Ultromics, a pioneer in AI-driven cardiology solutions, has unveiled the latest enhancement to EchoGo® Heart Failure: the introduction of a first-of-its-kind AI-powered probability scoring system for assessing heart failure with preserved ejection fraction (HFpEF). This innovation marks a groundbreaking development the use of deep learning to improve the detection of this often underrecognized condition.
EchoGo® Heart Failure remains the first and only AI platform capable of identifying HFpEF from a routine echocardiogram. The new probability scoring system builds upon this unique capability by generating a continuous score of the likelihood of disease, which provides a more nuanced diagnostic assessment of HFpEF, minimizing uncertainty and enhancing clinical decision-making. Additionally, the platform continues to support the detection of other critical heart conditions, such as cardiac amyloidosis, helping clinicians in the early identification of underlying causes of heart failure.
Also Read: LillyDirect platform expands to facilitate access to Alzheimer’s disease care
“The introduction of the probability scoring feature into the EchoGo® Heart Failure platform represents a pivotal step forward in heart failure detection and patient risk stratification,” said Ross Upton, PhD, Founder, CEO, and Chief Scientific Officer of Ultromics. “By delivering a precise probability score, EchoGo® Heart Failure enables clinicians to assess a patient’s likelihood of disease, allowing for more confident decision-making”.
SOURCE: PRNewswire